GTBP · GT Biopharma, Inc.

0001493152-26-023346

Summary

GT Biopharma reported a materially wider operating and net loss in Q1 FY2026 versus Q1 FY2025, driven by increased selling, general and administrative expenses — primarily marketing-related — and the absence of a prior-year vendor payable settlement benefit.

Key takeaways

Operating income declined to -$2.8M from -$1.9M YoY (-47.4%), reflecting higher SG&A expenses, including increased marketing spend.
Diluted EPS improved to -$0.11 from -$0.33 YoY (66.7%), attributable to an increase in weighted-average diluted shares outstanding following preferred stock issuances and warrant exercises.
Net cash used in operating activities was -$2.5M in Q1 FY2026, compared to -$2.2M in Q1 FY2025, consistent with the trend of sustained operating losses since inception.
The Company continues to operate under the going concern assumption, with unaudited financial statements prepared on that basis per management commentary.

Full analysis

Operating Income

Net Income and EPS

Cash Flow from Operations

Going Concern and Liquidity Context

Management states the unaudited condensed financial statements have been prepared assuming the Company will continue as a going concern. This disclosure underscores the importance of continued financing activity and operational execution, particularly given the Company’s history of sustained operating losses since inception and expectations that such losses will continue into the foreseeable future.